- Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
-
Fukunaga S, Mukasa M, Nakano D, Tsutsumi T, Kawaguchi T
- KMID: 2549391
- Clin Mol Hepatol.
- 2024 Jan;30(1):121-123.
- doi: 10.3350/cmh.2023.0437
-
- CITED
-
- Close
- SHARE
-
- Close
- Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
-
Suzuki H, Tsutsumi T, Kawaguchi M, Amano K, Kawaguchi T
- KMID: 2557402
- Clin Mol Hepatol.
- 2024 Jul;30(3):577-579.
- doi: 10.3350/cmh.2024.0157
-
- CITED
-
- Close
- SHARE
-
- Close
- Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
-
Suzuki H, Tsutsumi T, Kawaguchi M, Amano K, Kawaguchi T
- KMID: 2560097
- Clin Mol Hepatol.
- 2024 Oct;30(4):962-964.
- doi: 10.3350/cmh.2024.0264
-
- CITED
-
- Close
- SHARE
-
- Close
- Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”
-
Nakamura T, Nakano M, Tsutsumi T, Amano K, Kawaguchi T
- KMID: 2560076
- Clin Mol Hepatol.
- 2024 Oct;30(4):705-708.
- doi: 10.3350/cmh.2024.0372
-
- CITED
-
- Close
- SHARE
-
- Close
- Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
-
Tsutsumi T, Nakano D, Kawaguchi M, Takahashi H, Kawaguchi T
- KMID: 2554432
- Clin Mol Hepatol.
- 2024 Apr;30(2):266-268.
- doi: 10.3350/cmh.2024.0028
-
- CITED
-
- Close
- SHARE
-
- Close
- Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
-
Takamura S, Teraki Y, Katayama E, Kawaguchi T, Kawaguchi M, Nakano D, Tsutsumi T, Nagoshi S, Nakama T, Torimura T
- KMID: 2528257
- Clin Mol Hepatol.
- 2022 Apr;28(2):269-272.
- doi: 10.3350/cmh.2022.0040
-
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Intractable Suspected Perilymph Fistula with Severe Depression
-
Goto F, Oishi N, Tsutsumi T, Ogawa K
- KMID: 2316381
- Psychiatry Investig.
- 2014 Oct;11(4):499-501.
- doi: 10.4306/pi.2014.11.4.499
A 68-year-old woman presented dizziness whenever she put her finger into the right ear and also complained of water-streaming tinnitus, which indicated she would have been suffering from perilymph fistula.... -
- CITED
-
- Close
- SHARE
-
- Close
- MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
-
Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T
- KMID: 2528243
- Clin Mol Hepatol.
- 2022 Apr;28(2):150-163.
- doi: 10.3350/cmh.2021.0310
Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of an L- and T-Type Calcium Channel Blocker on 24-Hour Systolic Blood Pressure and Heart Rate in Hypertensive Patients
-
Komukai M, Tsutsumi T, Ebado M, Takeyama Y
- KMID: 2225015
- Korean Circ J.
- 2012 Apr;42(4):231-238.
- doi: 10.4070/kcj.2012.42.4.231
BACKGROUND AND OBJECTIVES: The aim of this study was to evaluate the effects of an L- and T-type calcium channel blocker (CCB) on 24-hour systolic blood pressure (24-hour SBP) and... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
-
Iwaki M, Fujii H, Hayashi H, Toyoda H, Oeda S, Hyogo H, Kawanaka M, Morishita A, Munekage K, Kawata K, Tsutsumi T, Sawada K, Maeshiro T, Tobita H, Yoshida Y, Naito M, Araki A, Arakaki S, Kawaguchi T, Noritake H, Ono M, Masaki T, Yasuda S, Tomita E, Yoneda M, Tokushige A, Kamada Y, Takahashi H, Ueda S, Aishima S, Sumida Y, Nakajima A, Okanoue T, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)
- KMID: 2554428
- Clin Mol Hepatol.
- 2024 Apr;30(2):225-234.
- doi: 10.3350/cmh.2023.0515
Background/Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently proposed as an alternative disease concept to nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the prognosis of patients with... -
- CITED
-
- Close
- SHARE
-
- Close
